Amplia Therapeutics halted enrollment in its Phase II Amplicity trial for advanced pancreatic cancer after three dose-limiting toxicities tied to the modified FOLFIRINOX regimen combined with narmafotinib (AMP-945). The company said no dose-limiting toxicities were reported with narmafotinib alone and that it is evaluating less toxic chemotherapy combinations. Patients already enrolled will remain on study and continue treatment. Amplia said it will adjust the regimen to pursue the clinical objective while addressing tolerability constraints identified by the trial’s safety monitoring. The move is a reminder of how combination-based oncology approaches can stumble at the dose-finding stage, even when targeted agents show separate tolerability signals.